20:31 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal; nephropathy; renal damage Mouse studies suggest FNDC5 or promoting PGC-1α expression could help treat nephropathy, chronic kidney disease (CKD) and kidney damage. In a mouse model of chemical-induced nephropathy, FNDC5 or skeletal muscle-specific...
08:00 , Mar 10, 2016 |  BC Innovations  |  Targets & Mechanisms

Brown fat heats up

While FGF21 is the clear frontrunner target for stimulating brown and beige fat, players in the seven year-old field believe there's room for plenty more runners in the race. Since the start of the year,...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fibronectin type III domain containing 5 (FNDC5; irisin)

Musculoskeletal disease INDICATION: Musculoskeletal Mouse studies suggest the skeletal muscle-derived myokine FNDC5 could help treat osteoporosis and other forms of bone loss. In normal mice, injection of human-mouse chimeric FNDC5 increased cortical bone mass and...
08:00 , Jan 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Fibronectin type III domain containing 5 (FNDC5; irisin) A study in mice and in patient serum identified irisin...